Search Results

There are 12877 results for: content related to: Phase 2 trial of docetaxel and gefitinib in the first-line treatment of patients with advanced nonsmall-cell lung cancer (NSCLC) who are 70 years of age or older

  1. Cost-utility and budget impact analyses of gefitinib in second-line treatment for advanced non-small cell lung cancer from Thai payer perspective

    Asia-Pacific Journal of Clinical Oncology

    Volume 8, Issue 1, March 2012, Pages: 53–61, Sumitra THONGPRASERT, Sirana TINMANEE and Unchalee PERMSUWAN

    Version of Record online : 28 FEB 2012, DOI: 10.1111/j.1743-7563.2012.01528.x

  2. You have free access to this content
    Results from a pilot Phase I trial of gefitinib combined with docetaxel and estramustine in patients with hormone-refractory prostate cancer


    Volume 106, Issue 9, 1 May 2006, Pages: 1917–1924, George Wilding, Patrick Soulie, Donald Trump, Ashis Das-Gupta and Eric Small

    Version of Record online : 27 MAR 2006, DOI: 10.1002/cncr.21831

  3. You have full text access to this OnlineOpen article
    Survival of patients with advanced lung adenocarcinoma before and after approved use of gefitinib in China

    Thoracic Cancer

    Volume 6, Issue 5, September 2015, Pages: 636–642, Yu-Tao Liu, Xue-Zhi Hao, Jun-Ling Li, Xing-Sheng Hu, Yan Wang, Zi-Ping Wang, Hong-Yu Wang, Bin Wang, Xiao-Hong Han, Xiang-Ru Zhang and Yuan-Kai Shi

    Version of Record online : 21 MAY 2015, DOI: 10.1111/1759-7714.12267

  4. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer

    Intervention Review

    The Cochrane Library

    Janette Greenhalgh, Kerry Dwan, Angela Boland, Victoria Bates, Fabio Vecchio, Yenal Dundar, Pooja Jain and John A Green

    Published Online : 25 MAY 2016, DOI: 10.1002/14651858.CD010383.pub2

  5. You have full text access to this Open Access content
    Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis

    Journal of Cellular and Molecular Medicine

    Volume 14, Issue 1-2, January-February 2010, Pages: 51–69, Luis Paz-Ares, Denis Soulières, Ivan Melezínek, Joachim Moecks, Lorenz Keil, Tony Mok, Rafael Rosell and Barbara Klughammer

    Version of Record online : 8 DEC 2009, DOI: 10.1111/j.1582-4934.2009.00991.x

  6. You have free access to this content
    Gefitinib versus pemetrexed as second-line treatment in patients with nonsmall cell lung cancer previously treated with platinum-based chemotherapy (KCSG-LU08-01)


    Volume 118, Issue 24, 15 December 2012, Pages: 6234–6242, Jong-Mu Sun, Ki Hyeong Lee, Sang-we Kim, Dae Ho Lee, Young Joo Min, Hwan Jung Yun, Hoon Kyo Kim, Hong Suk Song, Yeul Hong Kim, Bong-Seog Kim, In Gyu Hwang, Keehyun Lee, Sook Jung Jo, Jae Won Lee, Jin Seok Ahn, Keunchil Park, Myung-Ju Ahn and for the Korean Cancer Study Group (KCSG)

    Version of Record online : 6 JUN 2012, DOI: 10.1002/cncr.27630

  7. You have free access to this content
    Targeted therapy: An evolving world of lung cancer


    Volume 16, Issue 1, January 2011, Pages: 13–21, Kwok-Chi LAM and Tony S. MOK

    Version of Record online : 16 AUG 2010, DOI: 10.1111/j.1440-1843.2010.01821.x

  8. Gefitinib inhibits the cross-talk between mesenchymal stem cells and prostate cancer cells leading to tumor cell proliferation and inhibition of docetaxel activity

    Journal of Cellular Biochemistry

    Volume 114, Issue 5, May 2013, Pages: 1135–1144, Cinzia Borghese, Lara Cattaruzza, Eliana Pivetta, Nicola Normanno, Antonella De Luca, Mario Mazzucato, Marta Celegato, Alfonso Colombatti and Donatella Aldinucci

    Version of Record online : 14 MAR 2013, DOI: 10.1002/jcb.24456

  9. You have free access to this content
    Comparison of gefitinib versus erlotinib in patients with nonsmall cell lung cancer who failed previous chemotherapy


    Volume 116, Issue 12, 15 June 2010, Pages: 3025–3033, Seung Tae Kim, Jeeyun Lee, Jeong-hoon Kim, Young-Woong Won, Jong-Mu Sun, Jina Yun, Yeon Hee Park, Jin Seok Ahn, Keunchil Park and Myung-Ju Ahn

    Version of Record online : 6 APR 2010, DOI: 10.1002/cncr.25130

  10. You have free access to this content
    Neoadjuvant chemotherapy/gefitinib followed by concurrent chemotherapy/radiation therapy/gefitinib for patients with locally advanced squamous carcinoma of the head and neck


    Volume 115, Issue 10, 15 May 2009, Pages: 2138–2146, John D. Hainsworth, David R. Spigel, Howard A. Burris III, Tiffanie M. Markus, Dianna Shipley, Michel Kuzur, Scott Lunin and F. Anthony Greco

    Version of Record online : 13 MAR 2009, DOI: 10.1002/cncr.24265

  11. You have free access to this content
    Gefitinib - a potential new treatment option in lung cancer

    Future Prescriber

    Volume 10, Issue 2, April 2009, Pages: 7–13, Dr Fiona Blackhall and Steve Chaplin

    Version of Record online : 28 APR 2009, DOI: 10.1002/fps.47

  12. You have free access to this content
    Phase II trial of neoadjuvant docetaxel and gefitinib followed by radical prostatectomy in patients with high-risk, locally advanced prostate cancer


    Volume 115, Issue 4, 15 February 2009, Pages: 784–791, Jacqueline Vuky, Christopher Porter, Christina Isacson, Matthew Vaughan, Paul Kozlowski, Vincent Picozzi and John Corman

    Version of Record online : 6 JAN 2009, DOI: 10.1002/cncr.24092

  13. Non-Small-Cell Lung Cancer

    Standard Article

    Wiley Handbook of Current and Emerging Drug Therapies

    Published Online : 15 SEP 2006, DOI: 10.1002/9780470041000.cedt012

  14. You have free access to this content
    Preliminary indication of survival benefit from ERCC1 and RRM1-tailored chemotherapy in patients with advanced nonsmall cell lung cancer: Evidence from an individual patient analysis


    Volume 118, Issue 9, 1 May 2012, Pages: 2525–2531, George R. Simon, Michael J. Schell, Mubeena Begum, Jongphil Kim, Alberto Chiappori, Eric Haura, Scott Antonia and Gerold Bepler

    Version of Record online : 25 OCT 2011, DOI: 10.1002/cncr.26522

  15. You have free access to this content
    Tumor inhibitory effect of gefitinib (ZD1839, Iressa) and taxane combination therapy in EGFR-overexpressing breast cancer cell lines (MCF7/ADR, MDA-MB-231)

    International Journal of Cancer

    Volume 120, Issue 1, 1 January 2007, Pages: 181–188, Daisuke Takabatake, Takeo Fujita, Tadahiko Shien, Kensuke Kawasaki, Naruto Taira, Seiji Yoshitomi, Hirotoshi Takahashi, Yoichi Ishibe, Yutaka Ogasawara and Hiroyoshi Doihara

    Version of Record online : 11 OCT 2006, DOI: 10.1002/ijc.22187

  16. You have free access to this content
    Maintenance therapy in nonsmall-cell lung cancer


    Volume 115, Issue 22, 15 November 2009, Pages: 5143–5154, Tony S. K. Mok and Suresh S. Ramalingam

    Version of Record online : 5 AUG 2009, DOI: 10.1002/cncr.24563

  17. You have free access to this content


    Volume 11, Issue s5, November 2006, Pages: A154–A304,

    Version of Record online : 16 OCT 2006, DOI: 10.1111/j.1440-1843.2006.00997.x

  18. EGFR Tyrosine Kinase Inhibitors and Monoclonal Antibodies: Clinical Trial Review

    Lung Cancer, Fourth Edition

    Kathryn F. Mileham, Edward S. Kim, William N. William, Pages: 406–420, 2014

    Published Online : 4 APR 2014, DOI: 10.1002/9781118468791.ch26

  19. You have free access to this content
    Detection of epidermal growth factor receptor mutations in plasma by mutant-enriched PCR assay for prediction of the response to gefitinib in patients with non-small-cell lung cancer

    International Journal of Cancer

    Volume 125, Issue 10, 15 November 2009, Pages: 2393–2399, Chen He, Ming Liu, Chengzhi Zhou, Jiexia Zhang, Ming Ouyang, Nanshan Zhong and Jun Xu

    Version of Record online : 15 JUN 2009, DOI: 10.1002/ijc.24653

  20. Gefitinib in advanced non-small cell lung cancer

    Internal Medicine Journal

    Volume 35, Issue 2, February 2005, Pages: 77–82, R. Sharma, M. Boyer, S. Clarke and M. Millward

    Version of Record online : 10 FEB 2005, DOI: 10.1111/j.1445-5994.2005.00776.x